SimonMed Imaging®, one of the nation's largest and most innovative outpatient medical imaging providers, today announced a strategic partnership with Lunit, a global leader in medical AI for cancer diagnostics and precision oncology, to deploy one of the industry's first large-scale custom foundation models for chest X-ray (CXR) report generation..

西蒙医学影像公司（SimonMed Imaging®），作为全美规模最大且最具创新力的门诊医学影像供应商之一，今日宣布与全球癌症诊断和精准肿瘤学医学人工智能领域的领导者Lunit建立战略合作伙伴关系，以部署业内首批大规模定制基础模型之一，用于生成胸部X光片（CXR）报告。

Foundation models, trained on vast multimodal datasets with millions of images, capture generic domain knowledge. By fine-tuning these models with site-specific data within a HIPAA-compliant environment that maintains the highest levels of privacy and data security, SimonMed will achieve the dual objectives of adaptability and local specialization, both essential for radiologist-level accuracy and consistency that existing generic AI models today cannot match..

基础模型通过训练海量多模态数据集（包含数百万张图像）获取通用领域知识。通过在符合HIPAA规定的环境中使用特定站点的数据对这些模型进行微调，同时保持最高级别的隐私和数据安全，SimonMed将实现适应性和本地专业化这两大目标，这对于达到现有通用AI模型无法匹敌的放射科医生级别的准确性和一致性至关重要。

Through Lunit's Foundation Model Services (FMS) platform, SimonMed will fine-tune Lunit's CXR foundation models using SimonMed's own imaging and reports, creating a tailored model that reflects the real clinical environment across its more than 175 locations. The resulting AI-enhanced workflow is designed to improve quality, boost speed, reduce variability in reporting, and drive greater standardization across one of the largest radiology networks in the country..

通过Lunit的基础模型服务（FMS）平台，SimonMed将利用其自身的影像和报告对Lunit的CXR基础模型进行微调，创建一个反映其遍布175个以上地点的真实临床环境的定制模型。由此产生的AI增强工作流程旨在提高质量、加快速度、减少报告中的差异，并推动全国最大的放射网络之一实现更高的标准化。

'This represents a leap forward in how radiology practices can deploy AI,' said Dr. John Simon, Founder and CEO of SimonMed Imaging. 'By training foundation models on our own patient population and reporting style, we're able to create AI that is highly intelligent, patient-friendly and uniquely ours.

“这代表了放射学实践中部署人工智能的一次飞跃，”SimonMed Imaging创始人兼首席执行官约翰·西蒙博士说道。“通过在我们自己的患者群体和报告风格上训练基础模型，我们能够创建出高度智能、对患者友好且独一无二的人工智能。”

This approach allows us to share and scale the latest technology with millions of SimonMed patients coast to coast. Our goal remains to deliver high-quality reporting across hundreds of sites while preserving the expertise and final judgment of our radiologists. It's practical innovation with immediate clinical impact, and a major step toward the future of AI-empowered imaging.'.

这种方法使我们能够与遍布全国的数百万SimonMed患者分享和扩展最新技术。我们的目标仍然是在数百个站点提供高质量的报告，同时保留我们放射科医生的专业知识和最终判断。这是一种具有直接临床影响的实用创新，也是迈向人工智能赋能影像未来的重大一步。'

FMS is also equipped with model-performance monitoring and drift-alerting capabilities, which aids continuous improvement of AI model performance.

FMS还配备了模型性能监控和漂移预警功能，有助于持续改进AI模型的性能。

'Radiology workflows differ dramatically across institutions, and foundation models allow AI to adapt to these local realities,' said Brandon Suh, CEO of Lunit. 'With FMS, providers like SimonMed can build high-performing models that reflect their own data and workflows in a matter of weeks. We're proud to work with a national leader that shares our vision for AI that is adaptive, scalable, and seamlessly integrated into the daily practice of radiology.'.

“放射学工作流程在不同机构之间差异巨大，而基础模型使人工智能能够适应这些本地实际情况，”Lunit首席执行官Brandon Suh表示。“通过FMS，像SimonMed这样的供应商能够在数周内构建出反映其自身数据和工作流程的高性能模型。我们很自豪能与一位认同我们对人工智能愿景的全国领导者合作，这种人工智能具有适应性、可扩展性，并能无缝集成到放射学的日常实践中。”

The CXR report-generation model is the first to be deployed on FMS. Models for mammography and digital breast tomosynthesis are planned for release in 2026. An expanded portfolio of multimodal foundation models encompassing various clinical use cases will follow.

胸部X光报告生成模型是首个部署在FMS上的模型。乳腺X光摄影和数字乳腺断层合成模型计划于2026年发布。随后将推出涵盖各种临床应用场景的多模态基础模型扩展组合。

This collaboration broadens the long-standing partnership between Lunit and SimonMed, furthering both organizations' commitment to improving access, consistency, and quality in medical imaging through scalable, clinically grounded AI innovations.

这项合作拓宽了Lunit与SimonMed之间长期的合作伙伴关系，进一步彰显了双方通过可扩展、基于临床的人工智能创新来改善医学影像获取、一致性和质量的承诺。

About SimonMed

关于西蒙医学

Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has more than 175 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others.

总部位于亚利桑那州斯科茨代尔的SimonMed是美国最大的门诊医学影像供应商和放射科诊所之一。SimonMed在11个州拥有超过175个网点，并配备200多名接受过亚专科培训的放射科医生。SimonMed提供全面的诊断扫描服务，包括3T MRI、CT、超声波、3D乳腺摄影、PET/CT、核医学、DEXA、X光等。

The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders.

该公司使用最新、最先进的诊断成像技术，同时保持了可负担性和可及性。西蒙医学是全球临床应用人工智能改善诊断的领导者之一，其在全球范围内大规模部署了相关技术，以提高早期乳腺癌检测和脑部疾病评估的准确性。

Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit simonone.com and simonmed.com..

通过其simonONE部门，SimonMed还处于个性化成像的前沿，用于疾病的早期诊断和治疗。欲了解更多信息，请访问simonone.com和simonmed.com。

About Lunit

关于Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum..

Lunit（KRX: 328130）成立于2013年，是通过人工智能攻克癌症的全球领导者。我们经过临床验证的解决方案涵盖医学影像、乳腺健康和生物标志物分析，助力在癌症护理过程中实现更早的检测、更明智的治疗决策以及更精确的结果。

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development..

Lunit 提供涵盖风险预测、早期检测到精准肿瘤学的综合套件。我们通过 FDA 认证的 Lunit INSIGHT 系列和乳腺健康解决方案，支持全球数千家医疗机构进行癌症筛查，同时 Lunit SCOPE 平台与全球制药和实验室领导者合作，用于生物标志物研究及伴随诊断开发。

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer.

Lunit 获得来自 65 个国家超过 10,000 个站点的信任，它将深厚的医学专业知识与不断扩展的数据集相结合，为患者、临床医生和研究人员带来可衡量的影响。总部位于首尔并在全球设有办事处，Lunit 正在推动全球抗击癌症的斗争。

Learn more at lunit.io/en..

请访问 lunit.io/en 了解更多。

Source: prnewswire.com

来源：prnewswire.com